Carfilzomib 30mg powder for solution for infusion vials
Requires a prescription from a doctor or prescriber
Carfilzomib is an injectable antineoplastic agent (IV only).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Carfilzomib
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Carfilzomib
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Carfilzomib on the MHRA register
Kyprolis 30mg powder for solution for infusion vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(10)
Carfilzomib for previously treated multiple myeloma (TA657)
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA727)
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA841)
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA897)
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)
Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma (TA1149)
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)
Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma (TA1133)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 30 studies.
Randomised trials: 6 · 2015–2025
Showing all 30 studies, sorted by most relevant.
P. Moreau, M. Dimopoulos, J. Mikhael, et al.
Lancet, 2021
- Progression-Free Survival
- Anti-Inflammatory Agents
- Dexamethasone
F. Gay, W. Roeloffzen, M. Dimopoulos, et al.
Blood, 2023
D. Dytfeld, T. Wróbel, K. Jamroziak, et al.
The Lancet. Oncology, 2023
- Multiple Myeloma
- Lenalidomide
- Antineoplastic Combined Chemotherapy Protocols
R. Mina, P. Musto, D. Rota-Scalabrini, et al.
The Lancet. Oncology, 2022
- Multiple Myeloma
- Hematopoietic Stem Cell Transplantation
- Lenalidomide
M. Dimopoulos, P. Moreau, A. Palumbo, et al.
The Lancet. Oncology, 2016
- Bortezomib
- Anemia
- Antineoplastic Combined Chemotherapy Protocols
M. Dimopoulos, H. Quach, M. Mateos, et al.
Lancet, 2020
- Antibodies, Monoclonal
- Antineoplastic Combined Chemotherapy Protocols
- Chronic Disease
K. Yong, T. Martin, M. Dimopoulos, et al.
The Lancet. Haematology, 2024
- Antineoplastic Combined Chemotherapy Protocols
- Dexamethasone
- Progression-Free Survival
L. Costa, S. Chhabra, E. Medvedova, et al.
Journal of Clinical Oncology, 2021
- Multiple Myeloma
- Lenalidomide
- Antibodies, Monoclonal
A. Stewart, S. Rajkumar, M. Dimopoulos, et al.
The New England journal of medicine, 2015
- Lenalidomide
- Antineoplastic Combined Chemotherapy Protocols
- Dexamethasone
Shaji Kumar, Susanna J. Jacobus, Adam D. Cohen, et al.
The Lancet. Oncology, 2020
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
1 hour
Mechanism
Carfilzomib is made up of four modified peptides and acts as a proteasome inhibitor.
Food interactions
None known
Human targets
6 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
27 mg/m
AUC, single IV dose of 27 mg/m^2 = 379 ng•hr/mL;
Carfilzomib does not accumulation in the systemic.…
Half-life
15 mg/m
Protein binding
97%
Volume of distribution
20 mg/m
Metabolism
Clearance
151 - 263 L/h
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L39392][L42350]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 746 interactions
Maximum tolerate dose = 15 mg/m^2
How the body processes this drug — absorption, distribution, metabolism, and elimination
AUC, single IV dose of 27 mg/m^2 = 379 ng•hr/mL;
Carfilzomib does not accumulation in the systemic. At doses between 20 and 36 mg/m2, there was a dose-dependent increase in exposure.
All metabolites are inactive.
Proteins and enzymes this drug interacts with in the body
The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex).
Within the 20S core complex, PSMB5 displays a chymotrypsin-like activity
Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Involved in the generation of spliced peptides resulting from the ligation of two separate proteasomal cleavage products that are not contiguous in the parental protein .
PMID:27049119
Acts as a major component of interferon gamma-induced sensitivity. Plays a key role in apoptosis via the degradation of the apoptotic inhibitor MCL1.
May be involved in the inflammatory response pathway. In cancer cells, substitution of isoform 1 (E2) by isoform 2 (E1) results in immunoproteasome deficiency. Required for the differentiation of preadipocytes into adipocytes
The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex)
PMID:33727065 PMID:34819510
The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB6 by PSMB9 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues
The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex)
Proteins that transport this drug across cell membranes
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
ATC L01XG02
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Carfilzomib
Additional database identifiers
Drugs Product Database (DPD)
22678
ChemSpider
9731489
BindingDB
50277889
ZINC
ZINC000049841054
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9542
GenAtlas
PSMB5
GeneCards
PSMB5
GenBank Gene Database
D29011
GenBank Protein Database
558526
Guide to Pharmacology
2406
UniProt Accession
PSB5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9545
GeneCards
PSMB8
Guide to Pharmacology
2408
UniProt Accession
PSB8_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9537
GenAtlas
PSMB1
GeneCards
PSMB1
GenBank Gene Database
D00761
GenBank Protein Database
220026
Guide to Pharmacology
2404
UniProt Accession
PSB1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9546
GeneCards
PSMB9
Guide to Pharmacology
2409
UniProt Accession
PSB9_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9539
GenAtlas
PSMB2
GeneCards
PSMB2
GenBank Gene Database
D26599
GenBank Protein Database
565649
Guide to Pharmacology
2405
UniProt Accession
PSB2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9538
GeneCards
PSMB10
UniProt Accession
PSB10_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:40
GenAtlas
ABCB1
GeneCards
ABCB1
GenBank Gene Database
M14758
GenBank Protein Database
307180
Guide to Pharmacology
768
UniProt Accession
MDR1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q15366934), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.